Common Contracts
6 similar Underwriting Agreement contracts by Endologix Inc /De/, New Senior Investment Group Inc., PDL Biopharma, Inc., others
TCG BDC, INC. (a Maryland corporation) [—] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [—], 2017Underwriting Agreement • June 5th, 2017 • TCG Bdc, Inc. • New York
TCG BDC, Inc., a Maryland corporation (the “Company”), confirms its agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch, Morgan Stanley & Co. LLC (“Morgan Stanley”), J.P. Morgan Securities LLC and Citigroup Global Markets Inc. are acting as Representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.01 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of [—] additional sh
SENESTECH, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 21st, 2016 • SenesTech, Inc. • Agricultural chemicals • California
17,500,000 Shares NEW SENIOR INVESTMENT GROUP INC. (a Delaware corporation) Common Stock $.01 par value UNDERWRITING AGREEMENTUnderwriting Agreement • June 29th, 2015 • New Senior Investment Group Inc. • Real estate investment trusts • New York
ENDOLOGIX, INC. (a Delaware corporation) 2.25% Convertible Senior Notes due 2018 UNDERWRITING AGREEMENTUnderwriting Agreement • December 6th, 2013 • Endologix Inc /De/ • Surgical & medical instruments & apparatus • New York
The undersigned, a stockholder and an officer and/or director of Endologix, Inc., a Delaware corporation (the “Company”), understands that Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with the Company providing for the public offering (the “Public Offering”) of $75,000,000 aggregate principal amount of the Company’s Convertible Senior Notes (the “Securities”). In recognition of the benefit that such an offering will confer upon the undersigned as a stockholder and an officer and/or director of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting Agreement that, during the period beginning on the date hereof and ending on the date that is 90 days from the date of the Underwriting Agreement (the “Lock-up Period”), the undersigned will not, wi
PETROLEUM DEVELOPMENT CORPORATION 6,500,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 16th, 2012 • Petroleum Development Corp • Crude petroleum & natural gas • New York
Petroleum Development Corporation, a Nevada corporation (the “Company”) confirms its agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (“BofA Merrill Lynch”), J.P. Morgan Securities LLC and Wells Fargo Securities, LLC and each of the other Underwriters named in Exhibit A hereto (collectively, the “Underwriters”, which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA Merrill Lynch, J.P. Morgan Securities LLC and Wells Fargo Securities, LLC are acting as representatives (in such capacity, the “Representatives”), with respect to the issue and sale by the Company of a total of 6,500,000 shares (the “Initial Securities”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Initial Securities set forth in said Exhibit A hereto, and with respect to the grant by the Company to the Underwrit
PDL BIOPHARMA, INC. (a Delaware corporation) 3.75% Convertible Senior Notes Due 2015 UNDERWRITING AGREEMENT Dated: May 10, 2011Underwriting Agreement • May 16th, 2011 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • New York
the restrictions imposed by this lock-up agreement shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event, as applicable, unless Merrill Lynch waives, in writing, such extension.
